Today

Agents

Chat

Arena

Discover

More

App

Vertex Pharmaceuticals Q2 Adjusted EPS USD 4.73 Vs. IBES Estimate USD 4.73 - VRTX News | Rallies

Vertex Pharmaceuticals Q2 Adjusted EPS USD 4.73 Vs. IBES Estimate USD 4.73

VRTX•2026-08-03

Q2 results and full-year outlook

Aug. 3 (Reuters) - Vertex Pharmaceuticals Q2 adjusted net income USD 1,207.3 million vs. IBES estimate USD 1,229 million.

Q2 EPS USD 4.31
Q2 revenue USD 3,333.9 million vs. IBES estimate USD 3,232 million
Outlook FY revenue USD 13,100-13,200 million vs. IBES estimate USD 13,065 million
Outlook FY revenue USD 13,100-13,200 million

Related News

Nurix Therapeutics Chief Legal Officer Christine Ring disposes of 16,589 common shares worth $382,324.26

NRIX•2026-08-03

Zurn Elkay Water Solutions files Form 3 for Executive VP, General Manager Arnaldo Arturo Hernandez Covarrubias

ZWS•2026-08-03

Black Stone Minerals Q2 Net Income USD 106.4 Million

BSM•2026-08-03

New Jersey Resources beats Q3 adjusted EPS estimates, tightens FY guidance

NJR•2026-08-03

Incorrect alerts on AH Realty Trust withdrawn

AHRT•2026-08-03